Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Tucatinib Plus First-Line Maintenance Under Exploration in Metastatic HER2+ Breast Cancer
June 8th 2022Tucatinib plus first-line standard-of-care maintenance therapy with trastuzumab and pertuzumab is being investigated for its ability to improve progression-free survival and maintain health-related quality of life in patients with HER2-positive metastatic breast cancer.
Dostarlimab Demonstrates Promising Response Rates in Advanced, Recurrent Endometrial Cancer
June 8th 2022Single-agent dostarlimab generated durable antitumor activity in patients with advanced or recurrent endometrial cancer with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease.
Asciminib Represents New Standard of Care for Patients With CML in Chronic Phase
June 7th 2022Asciminib continued to demonstrate durable, major molecular responses as well as a tolerable safety profile vs bosutinib suggesting a long-term benefit in adult patients with chronic myelogenous leukemia in chronic phase who have been previously treated with 2 tyrosine kinase inhibitors.
Cobimetinib/Vemurafenib Combo Showcases Antitumor Activity in BRAF-Mutated Solid Tumors
June 7th 2022A combination comprised of cobimetinib and vemurafenib demonstrated evidence of antitumor activity in patents with advanced solid tumors harboring BRAF V600E and other mutations who are not otherwise eligible to receive other FDA-approved therapies.
Adagrasib Delivers Durable CNS-Specific Activity in KRAS G12C+ NSCLC
June 7th 2022Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.
Afatinib Efficacy and Safety to Be Investigated in Metastatic Solid Tumors With NRG1 Fusions
June 7th 2022Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.
Selinexor Demonstrates PFS Benefit in Advanced Endometrial Cancer, Including p53 Wild-Type Tumors
Selinexor generated a longer median progression-free survival compared with placebo in patients with advanced or recurrent endometrial cancer, including those with p53 wild-type tumors.
The combination of PDS0101 and pembrolizumab led to encouraging responses and favorable safety with no grade 3 or greater treatment-related adverse effects in patients with checkpoint inhibitor–naïve HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, according to findings from a prespecified interim analysis of the phase 2 VERSATILE-002 study.
Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma
The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.
Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%
June 7th 2022Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of at least 90% vs those with a tumor proportion score between 50% and 89%, according to 3-year findings from a correlative analysis.
Larotrectinib Delivers Durable Improvement in HRQoL in TRK Fusion Cancers
June 7th 2022Treatment with larotrectinib led to early onset and clinically meaningful improvements in health-related quality of life that were sustained for more than 12 months in most adult and pediatric patients with TRK fusion lung cancer, according to results from an expanded dataset.
Panitumumab Plus Intensified Chemotherapy Fails to Improve Efficacy in mCRC
June 7th 2022The EGFR inhibitor panitumumab plus a stronger chemotherapy regimen did not demonstrate a significant response benefit over an active chemotherapy comparator plus panitumumab in patients with metastatic colorectal cancer with unmutated RAS and BRAF.
Pembrolizumab/Chemoradiation Maintains Efficacy in Previously Untreated Stage III NSCLC
June 7th 2022Pembrolizumab plus concurrent chemoradiation, followed by single-agent pembrolizumab, maintained survival benefits in patients with previously untreated, locally advanced stage III non–small cell lung cancer.
Ribociclib Dose Reductions Do Not Affect Survival Outcomes in HR+/HER2- Advanced Breast Cancer
June 7th 2022Overall survival outcomes for patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib in the phase 3 MONALEESA-2 trial were comparable to those seen among patients who received the standard dose.
Sugemalimab and Chemotherapy Displays Significant OS Improvement in NSCLC
June 7th 2022Sugemalimab plus chemotherapy improved overall survival (OS) vs placebo plus chemotherapy in patients with newly diagnosed metastatic non–small cell lung cancer, irrespective of PD-L1 expression or tumor histology.
Radiotherapy Unnecessary for Some Luminal A Breast Cancers
Radiotherapy can safely be omitted from treatment plans following breast conserving surgery without jeopardizing recurrence rates for patients aged 55 years and older who have low-grade, T1N0, luminal A breast cancer with a Ki67 expression of 13.25% or less, according to findings from the LUMINA study.
Select Biomarkers Signal Worse Survival Outcomes With Apalutamide/ADT in mCSPC
June 7th 2022Circulating tumor DNA, select androgen receptor, and non-AR biomarkers have been identified as potential prognostic indicators of overall survival benefit for apalutamide plus androgen-deprivation therapy for patients with metastatic castration-sensitive prostate cancer.
Dostarlimab Elicits Clinical Complete Response Among All Treated Patients with dMMR Rectal Cancer
June 7th 2022Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor among 14 patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.
Adjuvant Pembrolizumab Demonstrates DFS Benefit in Key Subgroups of Resected Early-Stage NSCLC
Adjuvant pembrolizumab was found to generally improve disease-free survival over placebo in patients with completely resected early-stage non–small cell lung cancer, irrespective of type of surgical resection, tumor size, and type or extent of adjuvant chemotherapy.
Significant Enrichment of CDKN2A/B Alterations Found in Patients With NSCLC and Brain Mets
June 7th 2022Significant enrichment of CDKN2A/B and cell cycle pathway alterations were observed in patients with non–small cell lung cancer and brain metastases vs extracranial disease, and a higher fraction of the genome was altered in these patients vs matched primary tumor controls.
